Roth Capital Affirms Sarepta (SRPT) at 'Buy'; Shapeshifting Bears Back to Where It Started
Tweet Send to a Friend
Roth Capital affirms its Buy rating and $50 price target on Sarepta Therapeutics (Nasdaq: SRPT)Analyst Debjit Chattopadhyay offered the following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
